Robin Sanderson

Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma

Claire Roddie, Lorna Neill, Wendy Osborne et al. · Blood Advances · 2023 · 142 citations · Full text

Medicine, Hematology, Oncology +17

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

Reuben Benjamin, Nitin Jain, Marcela V. Maus et al. · The Lancet Haematology · 2022 · 136 citations · Full text

Life Sciences, Hematology, Immunology +14

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

Eleanor Barnes, Carl S. Goodyear, Michelle Willicombe et al. · Nature Medicine · 2023 · 133 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Anne M. Spanjaart, Per Ljungman, Rafael de la Cámara et al. · Leukemia · 2021 · 116 citations · Full text

Medicine, Hematology, Infectious Diseases +16

A national service for delivering <scp>CD19 CAR‐T</scp>in large B‐cell lymphoma – The <scp>UK</scp> real‐world experience

Andrea Kühnl, Claire Roddie, Amy A. Kirkwood et al. · British Journal of Haematology · 2022 · 112 citations

Medicine, Hematology, Oncology +14